NCT03361852 2026-03-25Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaDana-Farber Cancer InstitutePhase 1 Active not recruiting20 enrolled
NCT02446457 2026-03-09Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaM.D. Anderson Cancer CenterPhase 2 Active not recruiting53 enrolled 10 charts